AOD-9604
Also known as AOD9604 · Anti-Obesity Drug 9604
A modified fragment of human growth hormone (amino acids 177–191) that stimulates fat metabolism without affecting blood glucose or IGF-1.
Definition
AOD-9604 is the C-terminal fragment of the human growth-hormone molecule — the portion responsible for lipolytic signalling, with the growth-promoting region removed. It stimulates fat breakdown and inhibits new fat storage via β3-adrenoceptor activity.
How Meto uses it.
AOD-9604 is not part of the Meto catalogue and is not prescribed in any current protocol. This entry stays as a reference definition for readers researching the molecule. Where it has been studied, the course was 300 mcg daily, subcutaneous, fasted AM, across a 12-week cycle with labs and body composition re-evaluated at the end.
Safety notes
- Contraindicated in active malignancy
- Avoid in pregnancy and lactation
- Does not elevate IGF-1 or affect fasting glucose
- Prohibited under WADA rules for competitive athletes
Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.
Common questions
Does AOD-9604 stack with semaglutide or tirzepatide?
Pharmacologically it doesn't conflict — AOD-9604 does not touch glucose or insulin signalling, so it runs in parallel without affecting GLP-1 pharmacokinetics or dosing. Meto no longer offers it, so this is background rather than a protocol option.
Will I see muscle gains on AOD-9604?
No. AOD-9604 is a selective lipolytic fragment with the growth-promoting region of HGH removed. It drives fat metabolism only. Lean-mass support comes from the GH-axis class instead — Meto's P2 stack uses sermorelin.
How long until results?
Fat-metabolism changes appear over weeks, not days. Study protocols ran 12 weeks with a labs + body-composition re-check, and reported shifts typically between week 6 and week 12.
Read More
Lipolysis
The biological breakdown of stored fat into free fatty acids — the mechanism targeted by AOD-9604 and Tesamorelin.
BiomarkerIGF-1Insulin-like Growth Factor 1
The primary blood marker of growth-hormone activity — the lab that gates any GH-axis protocol and the one re-checked at month 3.
PeptideGLP-1 Receptor AgonistGLP-1 RA
A peptide drug class that mimics glucagon-like peptide-1 to slow gastric emptying, sharpen insulin response and quiet food-noise.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.